molecules and infectious diseases
ImmTAV (Immune mobilising mTCR Against Virus) molecules are novel bispecific molecules that, like ImmTAC (Immune mobilising monoclonal TCRs Against Cancer) molecules, are designed to enable the immune system to recognize and eliminate virally infected cells.
Immunocore aims to achieve sustained loss of circulating viral antigens and markers of viral replication after stopping medication for people living with chronic hepatitis B. This is known as “functional cure.”
About Immunocore
Immunocore is a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, infectious and autoimmune. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including five clinical stage progra
eureKARE launches with $60 million to build and finance next generation biotech companies in Europe streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Immunocore Holdings Limited: Immunocore Reports First Quarter 2021 Financial Results
Launched includes
$287 million in net proceeds from initial public offering and concurrent private placement in February 2021
Holdings Plc (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, today announced its results for the quarter ended March 31, 2021.
Highlights for the quarter included the presentation of the Phase 3 randomized data from the Company s lead candidate tebentafusp in the plenary clinical trial session at the American Association for Cancer Research (AACR) Annual Meeting, the launch of a global early access program for tebentafusp, and the successful completion of the Company s initial public offering resulting in net proceeds of $287 million.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Indigo Diabetes Appoints Paul Moraviec as Chairman of the Board
Indigo Diabetes N.V.May 12, 2021 GMT
Indigo Diabetes Appoints Paul Moraviec as Chairman of the Board
Brings decades of leadership experience in the Global MedTech sector
As CEO of ConvaTec Group Plc,
led the $
Transformed Abbott’s Diabetes Care EMEA division
BELGIUM - Ghent, May 12, 2021 – Indigo Diabetes N.V. (‘Indigo’ or the ‘Company’), a pioneering developer of medical solutions using nanophotonics, is pleased to announce the appointment of Paul Moraviec as Chairman of its Board of Directors.